Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0W2FZ
|
|||
| Former ID |
DIB008499
|
|||
| Drug Name |
Solithromycin
|
|||
| Synonyms |
Solithromycin; CEM-101; OP-1068; OPT-1068; Solithromycin (iv, bacterial pneumonia), Cempra; Solithromycin (malaria), Cempra/Medicines for Malaria Venture; Solithromycin (oral, bacterial pneumonia), Cempra; CEM-101 (iv, bacterial pneumonia), Cempra; CEM-101 (malaria), Cempra/Medicines for Malaria Venture; CEM-101 (oral, bacterial pneumonia), Cempra
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Bacillus anthracis infection [ICD-11: 1G40] | Phase 3 | [1] | |
| Company |
Cempra pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C43H65FN6O10
|
|||
| Canonical SMILES |
CCC1C2(C(C(C(=O)C(CC(C(C(C(=O)C(C(=O)O1)(C)F)C)OC3C(C(CC(O3)C)N(C)C)O)(C)OC)C)C)N(C(=O)O2)CCCCN4C=C(N=N4)C5=CC(=CC=C5)N)C
|
|||
| InChI |
1S/C43H65FN6O10/c1-12-32-43(8)35(50(40(55)60-43)19-14-13-18-49-23-30(46-47-49)28-16-15-17-29(45)21-28)26(4)33(51)24(2)22-41(6,56-11)37(27(5)36(53)42(7,44)39(54)58-32)59-38-34(52)31(48(9)10)20-25(3)57-38/h15-17,21,23-27,31-32,34-35,37-38,52H,12-14,18-20,22,45H2,1-11H3/t24-,25-,26+,27+,31+,32-,34-,35-,37-,38+,41-,42+,43-/m1/s1
|
|||
| InChIKey |
IXXFZUPTQVDPPK-ZAWHAJPISA-N
|
|||
| CAS Number |
760981-83-7
|
|||
| PubChem Compound ID | ||||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | No significant change | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bacteroides was not significantly changed by Solithromycin. | |||
|
Studied Microbe: Prevotella
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Saliva | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Prevotella was decreased by Solithromycin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
|
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Bifidobacterium was decreased by Solithromycin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Fusobacteriales | ||||
|
Studied Microbe: Leptotrichia
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Saliva | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Leptotrichia was decreased by Solithromycin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
|
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Enterococcus was decreased by Solithromycin. | |||
|
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Faeces, saliva | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Lactobacillus was decreased by Solithromycin. | |||
|
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Saliva | |
| Disease or Condition | Healthy | |||
| Description | The abundance of Streptococcus was decreased by Solithromycin. | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
|
Studied Microbe: fusobacteria
Show/Hide Hierarchy
|
[2] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experimental Species | Human | Experimental Sample | Saliva | |
| Disease or Condition | Healthy | |||
| Description | The abundance of fusobacteria was decreased by Solithromycin. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bacterial 50S ribosomal RNA (Bact 50S rRNA) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01756339) Efficacy and Safety Study of Oral Solithromycin (CEM-101) Compared to Oral Moxifloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia. U.S. National Institutes of Health. | |||
| REF 2 | Ecological Effect of Solithromycin on Normal Human Oropharyngeal and Intestinal Microbiota. Antimicrob Agents Chemother. 2016 Jun 20;60(7):4244-51. | |||
| REF 3 | Company report (cempra) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.